Pluristem Therapeutics Inc. (PSTI) Research

Pluristem Therapeutics Inc., an Israeli biotechnology firm founded in 2001 and based in Haifa, specializes in the discovery, advancement, clinical assessment, and production of innovative cell-based therapeutic products. The company's primary focus is on addressing a spectrum of severe medical conditions, including those related to reduced blood flow (ischemia), inflammation, blood disorders, and autoimmune dysfunctions, using its proprietary technologies. A cornerstone of their product pipeline involves placental expanded (PLX) based cell therapies. Their leading investigational drug, PLX-PAD, is currently undergoing evaluation in several clinical studies: it's in a late-stage (Phase III) trial to aid recovery after hip fracture surgery, a mid-stage (Phase II) trial for treating acute respiratory distress syndrome linked to COVID-19, and an early-to-mid-stage (Phase I/II) trial for severe graft-versus-host disease that has not responded to steroid treatment. Another significant product, PLX-R18, has successfully completed its initial Phase I clinical trial for individuals experiencing incomplete blood cell recovery following hematopoietic cell transplantation. Additionally, Pluristem is conducting preclinical animal studies to investigate PLX-R18's potential for treating acute radiation syndrome. The company also engages in various strategic collaborations: it holds a licensing agreement that facilitates PLX-PAD clinical trials in South Korea; participates in the nTRACK project, which explores labeling stem cells with gold nanoparticles; and has a unique partnership with NASA's Ames Research Center to assess how PLX cell therapies might prevent or alleviate medical issues encountered during space missions.

Open Pluristem Therapeutics Inc. (PSTI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.